

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/046730 A2

(51) International Patent Classification⁷: **A61K 47/48**,
A61P 31/04

(21) International Application Number:
PCT/US2004/037896

(22) International Filing Date:
12 November 2004 (12.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/519,100 12 November 2003 (12.11.2003) US

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.** [US/US]; Boyd Graduate Studies Research Center, Athens, GA 30602-7411 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALTMAN, Elliot** [US/US]; 210 Great Oak Drive, Athens, GA 30605-4505 (US). **WALKER, Jennifer, R.** [US/US]; 2980 Rocky Branch Road, Bogart, GA 30622 (US).

(74) Agent: **SANDBERG, Victoria, A.**; Mueiting, Raasch & Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2005/046730 A2

(54) Title: BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

(57) Abstract: Biotinylation of compounds such as peptides and peptidomimetics facilitates illicit transport of the compounds into Gram negative bacteria.

BIOTIN-FACILITATED TRANSPORT IN GRAM NEGATIVE BACTERIA

This application claims the benefit of U.S. Provisional Application Serial
5 No. 60/519,100, filed November 12, 2003, which is incorporated herein by
reference in its entirety.

BACKGROUND OF THE INVENTION

10 The outer membrane of Gram negative bacteria functions as a molecular
sieve and allows only very small molecules to passively diffuse into the cell.
Porins in the outer membrane allow the transport of larger molecules and may be
specific or non-specific in their molecular recognition. Non-specific porins such
as Omp F, Omp C and Pho E allow the rapid passage of hydrophilic molecules.
15 Other porins allow the transport of specific molecules. The peptide permeases,
for example, have a specificity for oligopeptides. The uptake of oligopeptides is
dependent upon size, hydrophobicity and charge.

It is well documented that *Escherichia coli* can not take up large peptides
and that the size exclusion limit for porin mediated peptide transport is 650
20 Daltons or the size of a penta- or hexapeptide. The size exclusion limit for
peptide uptake in other Gram negative organisms such as *Salmonella*
typhimurium has also been determined and found to be similar to that of *E. coli*
(Payne, 1980, "Transport and utilization of peptides by bacteria," p. 211-256. In
J. W. Payne (ed.), Microorganisms and Nitrogen Sources. John Wiley & Sons,
25 Chisester; Payne et al., 1994, Adv. Microb. Physiol. 36:1-80). In contrast to
Gram negative bacteria, Gram positive bacteria can transport much larger
peptides. For example, *Lactococcus lactis* has been shown to take up peptides
over 18 residues in length or 2,140 daltons in size (Detmers et al., 1998,
Biochemistry 37:16671-16679) while *Bacillus megaterium* can transport
30 molecules up to 10,000 daltons in size (Scherrer et al., 1971, J. Bacteriol.
107:718-735).

Pathogenic Gram negative bacteria represent a serious threat to public health. The American Medical Association and the Centers for Disease Control and Prevention have become increasingly concerned about the dramatic increase in drug-resistance pathogens. The data below shows the incidence of Gram

5 negative drug-resistant pathogens is the most problematic, totaling 59.9% of all drug-resistant pathogens that are monitored.

10 Table I. Incidence of antimicrobial-resistant pathogens that are monitored by the CDC.

<u>Antimicrobial-resistant pathogen</u>	Number of cases	Percent of total
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)	49,247	14.3%
Methicillin-resistant coagulase-negative <i>Staphylococci</i> (MRCNS)	29,453	8.5%
Vancomycin-resistant <i>Enterococcus</i> spp (VRE)	36,114	10.5%
Ceftazidime, ciprofloxacin/ofloxacin, imipenem, piperacillin, or levofloxacin-resistant <i>Pseudomonas aeruginosa</i>	109,165	31.6%
Ceftazidime, cefotaxime, ceftriaxone, imipenem, or meropenem-resistant <i>Enterobacter</i> spp	17,252	5.0%
Ceftazidime, cefotaxime, or ceftriaxone-resistant <i>Klebsiella pneumoniae</i>	16,834	4.9%
Ceftazidime, cefotaxime, ceftriaxone, ciprofloxacin, ofloxacin, or levofloxacin-resistant <i>Escherichia coli</i>	80,729	23.4%
Cefotaxime/ceftriaxone, or penicillin-resistant <i>Pneumococci</i>	6,328	1.8%
TOTAL	345,122	100.0%

15 Data compiled from the CDC National Nosocomial Infections Surveillance (NNIS) August 2002 Report of Antimicrobial-Resistant Pathogens in Hospitals.

Thus, despite many medical advances, the need for antibiotics effective against Gram negative bacteria continues to increase. Unfortunately, the current size and specificity limitations on uptake of molecules by Gram negative bacteria present obstacles to the use cellular uptake machinery to deliver compounds of

20 interest, such as antibiotics, to these pathogens. Compounding this problem is the inability of the pharmaceutical industry to readily generate new antibiotics. Pharmaceutical companies have relied on making derivatives of naturally

available compounds for several decades now as evidenced by the multiple generations of new antibiotics from drug classes such as penicillins, cephalosporins, and aminoglycosides. There has been increasing interest in the development of novel peptide antibiotics, however research has focused on the
5 development of peptide antibiotics for Gram positive pathogens due to the problem of peptide uptake by Gram negative pathogens.

Expansion of the size and type of molecules that can be taken up by Gram negative bacteria would open the door to numerous additional scientific and medical applications.

10

SUMMARY OF THE INVENTION

The invention provides a method for biotin-facilitated introduction of a compound into a bacterial cell, preferably a Gram negative bacterial cell. The
15 compound to be introduced into the cell is biotinylated, and the biotinylated compound is contacted with the cell to effect delivery of the compound to the cell. Advantageously, the biotinylated compound can pass through both the inner and outer cell membranes and is delivered to the cytosol of the cell.

The compound delivered to the Gram negative cell according to the
20 invention is not limited. Preferably, the compound includes an antimicrobial compound. Delivery of a peptide or peptidomimetic (naturally occurring or synthetic), preferably a peptide or peptidomimetic having antimicrobial activity against a Gram negative bacterium, is preferred. The method of the invention makes possible the relatively simple and reliable uptake of small, medium and
25 large peptides by Gram negative bacteria, paving the way to discovery, design, testing and use of new peptide antibiotics effective against Gram negative pathogens.

A biotinylated compound can be delivered to any Gram negative bacterial cell capable of transporting biotin from the extracellular environment to the
30 intracellular environment. Examples of Gram negative bacterial cells include cells of the genus *Escherichia*, *Salmonella*, or *Pseudomonas*. Preferably, the Gram negative bacterial cell is a pathogenic cell, and the compound that is

delivered to the cell includes a therapeutic, diagnostic or imaging agent and/or has antimicrobial activity. No pretreatment of the bacterial cell is needed prior to introduction of the biotinylated compound. For example, the method can be performed in the absence of a membrane-permeabilizing agent, such as calcium chloride.

The method of the invention optionally includes linking, covalently or noncovalently, a biotin moiety to the compound to yield the biotinylated compound. Preferably, the biotin moiety is covalently linked to the compound, for example through a biotin carboxyl group.

A biotinylated compound, such as a peptide or peptidomimetic, which itself may or may not be bioactive, is optionally conjugated to a second, preferably bioactive, compound, thereby facilitating biotin-facilitated transport of the second compound into the cell. Alternatively or additionally, the biotinylated compound optionally includes a targeting moiety that specifically targets a Gram negative bacterial cell and/or a targeting moiety that specifically targets a host eukaryotic cell. The targeting moiety can take the form of, for example, a receptor ligand or an antibody or fragment thereof.

Biotin-facilitated introduction of a compound into a Gram negative cell can be used to identify a compound having antimicrobial activity. A Gram negative bacterial cell is contacted with biotinylated compound to cause uptake of the biotinylated compound by the cell, and a determination is made as to whether the biotinylated compound has an antimicrobial effect on the cell. For example, the compound may inhibit the growth of the cell, up to and including causing cell death. The invention further encompasses antimicrobial compounds identified according to the screening method, as well as pharmaceutical compositions, methods of making pharmaceutical compositions, and uses thereof for the treatment or prevention of disease in plants and animals, particularly disease caused by Gram negative bacteria.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the chemical structure of biotin.

5 Figure 2 shows uptake of a 10 amino acid (aa) biotinylated peptide by (A) *S. aureus* and (B) *E. coli* MG1655 (B). The biotinylated peptide was added to mid-log cultures, samples were taken at different time intervals and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) as described in Example I. Peptide-only and cell-only samples were included as
10 controls.

Figure 3 shows the effect of biotin on the uptake of a 31 amino acid (aa) biotinylated peptide in *E. coli* and *S. aureus*. Biotinylated peptide and equimolar or 10X equimolar amounts of biotin or thiamine were added to mid-log cultures. The cell samples were processed and analyzed by SDS PAGE as described in
15 Example I.

Figure 4 shows the effect of avidin on the uptake of a 31 amino acid (aa) biotinylated peptide in *E. coli*. Biotinylated peptide and equimolar or 10X equimolar amounts of avidin or bovine serum albumin were added to mid-log cultures. The cell samples were processed and analyzed by SDS PAGE as
20 described in Example 1.

Figure 5 shows the effect of carbonyl cyanide m-chlorophenylhydrazone (CCCP) on the uptake of a 31 amino acid biotinylated peptide in *E. coli*. CCCP was added at a final concentration of 50 μ M to mid-log cultures of MG1655 since it has been shown that *E. coli* continues to grow normally at this concentration of
25 CCCP (Kinoshita et al., 1984, J. Bacteriol. 160:1074-1077). The cell samples were processed and analyzed by SDS PAGE as described in Example I.

Figure 6 shows the effect of a *birB*⁻ mutation on the uptake of a 31 amino acid (aa) biotinylated peptide in *E. coli*. The biotinylated peptide was added to mid-log cultures of *birB*⁺ and *birB*⁻ cells. After 10 minutes of incubation the cell
30 samples were processed and analyzed by SDS PAGE as described in Example I. Peptide-only and cell-only samples were included as controls.

Figure 7 shows growth of an *E. coli bio* auxotroph on minimal media supplemented with biotin or equimolar amounts of biotinylated peptides. The *E. coli* SA291 *bio* auxotrophic strain was grown in minimal media at 37°C with either no supplement (Δ), 1 μ g/mL biotin (\square), or equimolar amounts of the 10
5 (O) and 31 (\diamond) amino acid biotinylated peptides. Aliquots were removed at 12 hour intervals and the OD₅₅₀ was determined.

Figure 8 shows localization of the biotinylated peptide in *E. coli*. Biotinylated peptide was added to mid-log cultures of MG1655 and the cells were fractionated into periplasmic, cytoplasmic, and membrane samples and
10 analyzed by SDS PAGE as described in Example I. Peptide-only and whole cell plus peptide samples were included as controls.

Figure 9 shows uptake of a 31 amino acid biotinylated peptide by (A) *S. typhimurium* and (B) *P. aeruginosa*. Biotinylated peptide was added to mid-log cultures, aliquots were taken at different time intervals and analyzed by SDS
15 PAGE as described in Example I. Peptide-only and cell-only samples were included as controls.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The present invention provides materials and methods for uptake of
20 biotinylated compounds by Gram negative bacteria. The biotin transport system is advantageously be used to accomplish "illicit transport" of biotinylated compounds into Gram negative bacteria. In "illicit transport," the entry of compounds into cells is accomplished through the use of transport systems designed for other substrates, in this case, biotin.

25 Biotinylated compounds can be transported into any Gram negative bacterium that has the ability to take up biotin from the extracellular environment, for example by passive or active transport through a biotin transporter system. The invention is not limited by the particular biotin transport mechanism used by the Gram negative bacterium. As used herein, the term
30 "biotin transporter" includes one or more components of a biotin transport system that permits the passage of biotin from the extracellular environment, across the cellular membrane(s) and preferably into the cytoplasm of a host cell. For

example, a biotin transporter can take the form of one or more membrane-bound biotin receptor molecules or a molecular complex that facilitates uptake of exogenous biotin by a cell. An example of a microbial biotin transporter is the biotin transporter *birB/bioP* found in *E. coli*.

5 A Gram negative bacterium is a bacterium with a cell wall structure that does not retain the methyl violet component of Gram's stain after elution with an organic solvent such as ethyl alcohol. The pink counterstain makes the bacteria appear pink. Gram negative bacteria are characterized by a two cellular membranes separated by a periplasmic space. The periplasmic space is external
10 to the inner, cytoplasmic membrane. On the other side of the periplasm is an outer membrane comprising lipopolysaccharide (LPS) and capsular polysaccharide. Porin proteins typically are present in the outer LPS layer. Gram negative bacteria include, without limitation, *Escherichia* spp. (e.g., *E. coli*); *Salmonella* spp. (e.g., *S. typhimurium*); *Pseudomonas* spp. (e.g., *P. aeruginosa*);
15 *Burkholderia* spp.; *Neisseria* spp. (*N. meningitidis*); *Haemophilus* spp. (*H. influenzae*); *Shigella* spp.; *Bacterioides* spp.; *Campylobacter* spp.; *Brucella* spp.; *Vibrio* spp.; *Yersinia* spp.; *Helicobacter* spp.; *Calymmatobacterium* spp.; *Legionella* spp.; *Leptospira* spp.; *Borrelia* spp.; *Bordetella* spp.; *Klebsiella* spp.; *Treponema* spp.; *Francisella* spp.; and *Gardnerella* spp. Many of these
20 organisms are known to be pathogenic to animals and/or plants, including mammals such as humans, and can cause diseases and disorders such as enteritis, septicemia, meningitis, enteric fever, pneumonia, epiglottitis, cellulitis, diarrhea and sexually transmitted diseases.

 "Biotinylation" of a compound refers to binding, whether covalent or
25 noncovalent, of a biotin molecule (including an analog or derivative thereof, or other ligand of a biotin transporter) to the compound. Biotinylated compounds as described herein may be singly or multiply biotinylated. When the term "biotin" is used herein, the term includes analogs and derivatives of biotin provided that they also enable or potentiate biotin-facilitated transport into the cell. Biotin
30 analogs are described in U.S. Pat. No. 5,416,016 (Low et al.) and include biocytin, biotin sulfoxide, oxybiotin and other biotin receptor-binding compounds. Other compounds capable of binding to a biotin transporter to

initiate biotin-mediated transport of the biotinylated compound include, for example, antibodies specific for the biotin transporter. For example, a compound complexed with an anti-biotin transporter antibody (monoclonal or polyclonal) could be used to initiate transmembrane transport of the complex in accordance with the present invention.

The invention is not limited by the type of compound that is biotinylated and delivered to the Gram negative bacterium, or by the type of linkage between the compound and the biotin. The compound to be delivered may possess a functional group that allows direct covalent or noncovalent linkage to a biotin molecule, or it may be derivatized with a linker or spacer molecule that possesses a functional group thereby allowing indirect covalent or noncovalent linkage of the compound to a biotin molecule. Covalent linkages such as amide, ester or imino bonds between acid, aldehyde, hydroxy, amino, or hydrazo groups on the biotin and the compound to be delivered (or the linker) are preferred.

The functional group on the compound (or the linker molecule) that participates in the linkage with the biotin molecule is preferably one that can form a covalent linkage with the carboxyl group of biotin (Fig. 1). Compounds containing amine groups (either naturally or by way of derivatization with a linker molecule) can be conveniently biotinylated by covalently linking the amine group of the compound to the carboxylic acid of biotin to form an amide bond. However, other conjugation strategies may be used without adversely affecting transmembrane transport of the biotinylated compound. For example, the carboxylic acid of the biotin can be covalently linked to other functional groups on the compound to be biotinylated. Alternatively, the covalent linkage between the biotin and the compound to be biotinylated can include one of the constituents of the biotin ureido ring (nitrogen, sulfur or carbon) or the carbonyl group on the ureido ring.

Well-known biotinylation methods are described in U.S. Pat. No. 5,416,016 (Low et al.). For example, biotinylation can be readily accomplished by activating the carboxyl group of the biotin such that it reacts with free amino groups of the compound to be delivered, such as a peptide or peptidomimetic. A biotinylating reagent such-as D-biotin-N-hydroxy-succinimide ester or biotinyl-

p-nitrophenyl ester can be used. The activated ester reacts under mild conditions with amino groups to incorporate a biotin residue into the desired molecule. The procedure to be followed for biotinylating macromolecules using D-biotin-N-hydroxy-succinimide ester is well known in the art (Hofmann et al.,
5 J.Am.Chem.Soc. 100, 3585-3590 (1978)). Procedures suitable for biotinylating an exogenous molecule using biotinyl- ϵ -nitrophenyl ester as a biotinylating reagent are also well known in the art (Bodanszk et al., J.Am.Chem.Soc, 99, 235 (1977)). Other reagents such as D-biotinyl- ϵ -aminocaproic acid N-hydroxy-succinimide ester in which ϵ -aminocaproic acid serves as a spacer link to reduce
10 steric hindrance can also be used for the purposes of the present invention.

As an example of a noncovalent linkage, hydrogen bonding between a biotinylated oligonucleotide and a complementary region on a nucleic acid to be delivered can be used to deliver the nucleic acid to a cell.

The term "compound" as used herein is not limited to a single molecule
15 but can include a complex of molecules, ions, and the like, including but not limited to heterogeneous or homogeneous multimolecular complexes, conjugates, chelated or caged complexes, and the like. Compounds whose transport into Gram negative bacteria can be facilitated by derivatization with a biotin moiety include, for example, biomolecules such as polypeptides, nucleic acids,
20 carbohydrates and lipids.

Polypeptides represent a class of compounds that is particularly amenable to transport through the biotin transporter. A polypeptide is a plurality of α -amino acids joined together in a linear chain via peptide bonds. The term "polypeptide" is inclusive of the terms peptide, oligopeptide and polypeptide. The amino acids
25 present in a polypeptide or peptide may include naturally occurring amino acids as well as other, non-naturally occurring amino acids or derivatives thereof such as 3-hydroxyproline, 4-hydroxyproline, homocysteine, 2-aminoadipic acid, 2-aminopimelic acid, γ -carboxyglutamic acid, γ -carboxyaspartic acid, ornithine, homoarginine, N-methyl lysine, dimethyl lysine, trimethyl lysine, 2,3-
30 diaminopropionic acid, 2,4-diaminobutyric acid, homoarginine, sarcosine, hydroxylysine, substituted phenylalanines, norleucine, norvaline, 2-aminooctanoic acid, 2-aminoheptanoic acid, statine, β -valine, naphthylalanines,

substituted phenylalanines, tetrahydroisoquinoline-3-carboxylic acid, and halogenated tyrosines.

It should be understood that the terms "peptide" or "polypeptide" do not connote a specific length of a polymer of amino acids, nor are they intended to
5 imply or distinguish whether the polypeptide is produced using recombinant techniques, chemical or enzymatic synthesis, or is naturally occurring. As the term is commonly used in the art, a "peptide" may have between 2 and about 50 or more amino acids, although peptides larger than about 50 amino acids in length are often referred to as polypeptides or proteins. For purposes of the
10 present invention, the term "peptide" is not limited to any particular number of amino acids. Preferably a peptide contains a quantity of amino acids that ranges from 2, 3, 4, 5, 8, 10, or 20 amino acids as a lower size limit, to 30, 40, 50, 60, 70, 80, 90 or 100 amino acids as an upper size limit, and any combination thereof. In various embodiments, the peptide contains, for example, between 2
15 and 80 amino acids; between 2 and 70 amino acids; between 2 and 50 amino acids; between 2 and 40 amino acids; between 5 and 80 amino acids; between 5 and 70 amino acids; between 5 and 50 amino acids; between 5 and 40 amino acids; between 10 and 80 amino acids; between 10 and 70 amino acids; between 10 and 50 amino acids; between 10 and 40 amino acids; and so on.

As used herein, the terms "polypeptide" and "peptide" include naturally occurring or synthetic peptides, as well as analogs and conjugates thereof. An "analog" of a peptide is one that has been modified by the addition, substitution, or deletion of one or more contiguous or noncontiguous amino acids, or that has been chemically or enzymatically modified, e.g., by attachment of a reporter
25 group, by an N-terminal, C-terminal or other functional group modification or derivatization, or by cyclization, as long as the analog retains the biological activity of the peptide. An analog can thus include additional amino acids at one or both of the termini of a polypeptide. As another example, a polypeptide can be acetylated, acylated, methylated, thiolated, esterified, or conjugated to another
30 molecule.

A peptidomimetic is a polymeric compound that is based on the structure of a parent peptide. However, a peptidomimetic contains non-peptidic structural

elements. For example, the backbone of a peptidomimetic may contain one or more nonpeptide bonds. Additionally or alternatively, one or more of the monomeric components of a peptidomimetic may be a component other than a naturally occurring -amino acid. For example, a peptidomimetic can include, without limitation, one or more D-amino acids or one or more other nonnaturally occurring monomeric components such as 3-hydroxyproline, 2-aminopimelic acid and dimethyl lysine, and the like as exemplified above. A peptidomimetic "mimics" a "peptide"; that is, it is capable of mimicking or antagonizing the biological action(s) of a reference peptide, such as a natural parent peptide. As set forth in "Glossary of Terms used in Medicinal Chemistry, a publication of the International Union of Pure and Applied Chemistry (IUPAC) (IUPAC Recommendations 1998), a peptidomimetic may be lacking in one or more classical peptide characteristics such as enzymatically scissile peptidic bonds. (Pure Appl. Chem. 70:1129-1143, 1998). For example, in a peptidomimetic, one or more peptide (amide) bonds in a polypeptide backbone may be replaced by another type of chemical bond, or the backbone atoms of carbon or nitrogen may be substituted by other backbone atoms. A peptidomimetic may be designed de novo, or it may represent a structure that is derived, by substitution, deletion, and or addition, from a parent peptide. However, it should be understood the term peptidomimetic does not include a naturally occurring polypeptide, or a polypeptide that is composed exclusively of naturally occurring -amino acids joined by peptide bonds.

In a preferred embodiment, the compound that is biotinylated and delivered to the Gram negative bacterium is a bioactive compound, preferably a bioactive peptide or peptidomimetic. A bioactive compound is a compound having a biological activity and/or detectability when delivered to a cell. A bioactive compound may directly or indirectly affects the structure or function of a target molecule, such as a component of a cell to which it is delivered. A bioactive compound may be capable of modulating or otherwise modifying cell function and includes pharmaceutically active compounds such therapeutic agents. Bioactive compounds also include diagnostic agents such as imaging agents, which associate with cell components and allow detection, classification

and/or quantification. Additional bioactive compounds that can be biotinylated and delivered according to the invention are described in U.S. Pat. No. 5,416,016 (Low et al.). They include without limitation organic molecules including natural products and toxins, metal-containing complexes, molecules containing
5 radioisotopes, dyes and contrast agents, and the like.

Examples of preferred bioactive compounds include antimicrobial peptides and drugs, particularly these effective against pathogenic Gram negative bacteria. Antimicrobial compounds are compounds that adversely affect a microbe such as a bacterium, virus, protozoan, or the like. Antimicrobial
10 compounds include, for example, inhibitory compounds that slow the growth of a microbe, microbiocidal compounds that are effective to kill a microbe (e.g., bacteriocidal and virocidal drugs, sterilants, and disinfectants), and compounds effective to interfere with microbial reproduction, host toxicity, or the like. Compounds that are toxic to Gram negative bacteria, such as antibiotics,
15 membrane-disrupting agents, nucleotide/nucleoside analogs, cytotoxic agents and the like, are particularly important candidates for delivery to Gram negative bacteria according to the invention. Such toxic compounds may arrest or inhibit the growth of the Gram negative bacteria, or may cause cell death.

It should be understood that the term "bioactivity" as used herein includes,
20 without limitation, any type of interaction with another biomolecule, such as a protein, glycoprotein, carbohydrate, for example an oligosaccharide or polysaccharide, nucleotide, polynucleotide, fatty acid, hormone, enzyme, cofactor or the like, whether the interactions involve covalent or noncovalent binding. Bioactivity further includes interactions of any type with other cellular
25 components or constituents including salts, ions, metals, nutrients, foreign or exogenous agents present in a cell such as viruses, phage and the like, for example binding, sequestration or transport-related interactions, as further described in U.S. Pat. No. 5,416,016 (Low et al.).

Bioactivity of a compound can be detected, for example, by observing
30 phenotypic effects in a host cell in which it is expressed, or by performing an *in vitro* assay for a particular bioactivity, such as affinity binding to a target molecule, alteration of an enzymatic activity, or the like.

Biotinylated peptides or peptidomimetics may themselves be bioactive and/or they can be conjugated to a bioactive "cargo" compound such as a therapeutic, diagnostic or imaging agent. Conjugation of a "cargo" compound to a biotinylated peptide or peptidomimetic facilitates delivery of the bioactive

5 "cargo" compound to Gram negative bacteria. The compound that is conjugated to the peptide can be any type of compound. Conjugation can take the form of a covalent or noncovalent linkage; preferably it is covalent. For example, the cargo molecule or complex may contain an avidin or streptavidin moiety that binds with the biotin on the biotinylated peptide or peptidomimetic. In that

10 embodiment, multiply biotinylated peptides or peptidomimetics are preferred so that biotin moieties are available for interaction with the cell's biotin transport system in order to facilitate uptake by the cell.

The biotin-facilitated transport mechanism of the invention can be advantageously employed to reliably target and deliver known and newly

15 discovered drugs to Gram negative bacteria via biotinylation of the drug. In some instances, biotin-mediated transport can serve as a secondary membrane transport system for a bioactive compound that already makes use of a different transmembrane transport system, thereby increasing efficacy by improving delivery to the target cell. In other instances, the bioactive compound can contain

20 a targeting moiety that is specific for Gram-negative bacteria, in addition to a biotin moiety for facilitated transport once the compound is in contact with the cell membrane. The term "targeting moiety" is not limited to a particular molecular feature but can include a functional group or larger moiety, or a separate molecular structure that is covalently or noncovalently linked to the

25 bioactive compound. For example, a targeting moiety may include a particular cell surface receptor ligand (e.g., a peptide or small organic molecule), or an antibody or fragment thereof that is capable of specific interaction with a component on the surface of a Gram negative bacterium.

The method of the invention involves contacting a biotinylated compound

30 with a Gram negative bacterium that possesses a biotin transporter for a time sufficient to allow binding of the biotin moiety to the transporter and uptake of the biotinylated compound. Contact between the biotinylated compound and the

Gram negative bacterium may be *in vitro*, as in cell culture, or *in vivo*. The present invention thus finds diagnostic, prognostic and therapeutic application in both the medical and veterinary fields, as well as application in basic and applied scientific research. For *in vitro* applications, the number of biotin transporters in
5 a cell membrane can be increased by growing the cells on biotin-deficient substrates to promote biotin transporter production, or by expression of an inserted heterologous gene encoding the biotin transporter.

It should be understood that the method of the invention is effective to transport a biotinylated compound into the cytoplasm of a Gram negative
10 bacterium. That is, the method is effective to cause the biotinylated compound to cross both the outer and inner membranes as well as the periplasmic place separating them. The inner membrane does not act as a barrier to transport and the biotinylated compound typically does not accumulate in the periplasmic space. Rather, significant amounts of the biotinylated compound are transported
15 into the cytosol of the cell. Amounts of the biotinylated compound may be found associated with either or both cell membranes as well, or with the periplasmic space. Notably, it is not necessary to pretreat cells prior to effecting biotin-facilitated transport of a compound of interest. For example, it is not necessary to make cells "competent" for transfer by pretreating in them with a permeabilizing
20 agent such calcium chloride to facilitate transport of a compound, such as a nucleic acid or a protein; indeed the method is preferably performed in the absence of agents such as calcium chloride.

The addition of glucose during biotin-mediated transport can increase the efficiency of transport. Thus, in a preferred embodiment, the biotinylated
25 compound is contacted to the Gram negative bacterial cell in the presence of glucose, preferably about 0.05 % to about 0.5% by weight; more preferably about 0.2% \pm 0.1% by weight.

Also provided by the invention is a method for screening candidate compounds for bioactivity, particularly antimicrobial activity directed against the
30 host Gram negative bacterium. The method involves contacting a candidate compound, which has been biotinylated, with a Gram negative bacterial cell to cause uptake of the biotinylated compound by the cell. A determination is then

made as to whether the compound has antimicrobial activity. One exemplary method for determining whether a compound has antimicrobial activity is to observe whether it has an inhibitory effect on cell growth. As the phrase is used herein, an "inhibitory effect" on cell growth is inclusive of both bacteriocidal
5 activity (i.e., killing/destroying of the bacterial cell) and bacteriostatic activity (i.e., inhibition of the growth and/or multiplication of bacteria without necessarily destroying the bacteria). Inhibition of cell growth can be evidenced, for example, by a reduction in cell doubling time, morphological changes, or a slowing down of the metabolism of the cells, up to and including a cytotoxic effect (cell death).
10 For example, an inhibitory effect on cell growth can be observed as a slowing down or reduction of turbidity of a growing cell culture. Other methods of determining antimicrobial effect are well known to the art. These methods may vary with the type of compound being screened.

The invention is intended to encompass antimicrobial compounds
15 identified according to the biotin-facilitated screening method set forth herein. Such antimicrobial compounds include the biotinylated form of an antimicrobial compound thus identified as well as the antimicrobial compound in a form that does not include a biotin moiety. The compounds identified according to the screening method may be known to the art, or they may be newly discovered as
20 part of a random or nonrandom screening process. These antimicrobial compounds are especially useful to treat or prevent disease caused by Gram negative bacteria, particularly to treat disease caused by a bacterium that served as the bacterial host used in the screening method to identify the antimicrobial compounds.

25 The invention also provides pharmaceutical compositions and medicaments that include antimicrobial compounds identified according to the biotin-facilitated screening method of the invention, and a pharmaceutically acceptable carrier. Additionally, the invention includes use of the antimicrobial compound for preparation of a pharmaceutical composition or medicament for
30 treatment of a disease caused by a Gram negative bacterium. The antimicrobial compounds are preferably peptides and peptidomimetics. As discussed above, the therapeutically active antimicrobial compound may or may not be

biotinylated. Preferably, the antimicrobial compound is biotinylated to facilitate cellular uptake of the antimicrobial compound.

Optionally, the antimicrobial compound used in the pharmaceutical composition of medicament, or administered to a patient, further includes a
5 targeting moiety that is specific for Gram negative bacteria. Incorporation of a moiety targeting a Gram negative bacterium may, in some instances, lessen or eliminate uptake of the antimicrobial compound by other cells in the host, which may in turn increase the effectiveness of the treatment, especially where the microbial infection is extracellular (i.e., present outside the eukaryotic host cells).

10 It may also be desirable to include in the antimicrobial compound, either additionally or alternatively, a targeting moiety that targets a eukaryotic host cell, including a selected host cell, tissue or organ. Targeting a eukaryotic host cell (or a specific type of cell, tissue, organ, etc.) may be particularly useful in instances where the Gram negative bacterium is an intracellular pathogen and is therefore
15 primarily present inside the animal or plant host cells.

The pharmaceutical composition is administered to a patient in an amount effective to produce the intended diagnostic or therapeutic effect. Medical and veterinary uses are contemplated. The patient is preferably an animal, more preferably a human or a domesticated animal, including a pet or a farm animal,
20 such as a cat, dog, horse, pig, chicken, and the like. In a particularly preferred embodiment, the patient is a human.

The compounds identified according to the screening method of the invention can also be administered to plants, such as agricultural and crop plants, to treat or prevent infection by Gram negative bacteria that are pathogenic to
25 plants. Preferably, such compounds are identified using a Gram negative plant pathogen as the host cell in the screening process.

Pharmaceutical compositions of the invention are administered to a subject in a variety of forms adapted to the chosen route of administration. The formulations include those suitable for oral, rectal, vaginal, topical, nasal,
30 ophthalmic or parenteral (including subcutaneous, intramuscular, intraperitoneal and intravenous) administration. Treatment can be prophylactic or, alternatively, can be initiated after known exposure to a pathogenic bacterium.

The formulations may be conveniently presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active compound into association with a carrier which constitutes one or more accessory ingredients. In general, the
5 formulations are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired formulations.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as tablets, troches, capsules, lozenges, wafers,
10 or cachets, each containing a predetermined amount of the antimicrobial compound as a powder or granules, as liposomes containing the antimicrobial compound, or as a solution or suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an elixir, an emulsion or a draught. The amount of antimicrobial compound in such therapeutically useful compositions is such that
15 the dosage level will be effective to reduce, ameliorate or eliminate the bacterial infection in the subject, preferably by causing the bacterial death.

Formulations suitable for parenteral administration conveniently comprise a sterile aqueous preparation of the antimicrobial compound, or dispersions of sterile powders comprising the antimicrobial compound, which are preferably
20 isotonic with the blood of the recipient. Isotonic agents that can be included in the liquid preparation include sugars, buffers, and sodium chloride. Solutions of the antimicrobial compound can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions of the antimicrobial compound can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid
25 polyethylene glycols, and the like), vegetable oils, glycerol esters, and mixtures thereof. The ultimate dosage form is sterile, fluid and stable under the conditions of manufacture and storage. The necessary fluidity can be achieved, for example, by using liposomes, by employing the appropriate particle size in the case of dispersions, or by using surfactants. Sterilization of a liquid preparation can be
30 achieved by any convenient method that preserves the bioactivity of the antimicrobial compound, preferably by filter sterilization. Preferred methods for preparing powders include vacuum drying and freeze drying of the sterile

injectible solutions. Subsequent microbial contamination can be prevented using various antimicrobial agents, for example, antibacterial, antiviral and antifungal agents including parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. Absorption of the antimicrobial compounds over a prolonged period can be
5 achieved by including agents for delaying, for example, aluminum monostearate and gelatin.

Nasal spray formulations comprise purified aqueous solutions of the antimicrobial compound with preservative agents and isotonic agents. Such formulations are preferably adjusted to a pH and isotonic state compatible with
10 the nasal mucous membranes. Formulations for rectal or vaginal administration may be presented as a suppository with a suitable carrier such as cocoa butter, or hydrogenated fats or hydrogenated fatty carboxylic acids. Ophthalmic formulations are prepared by a similar method to the nasal spray, except that the pH and isotonic factors are preferably adjusted to match that of the eye. Topical
15 formulations comprise the antimicrobial compound dissolved or suspended in one or more media such as mineral oil, petroleum, polyhydroxy alcohols or other bases used for topical pharmaceutical formulations. The compound of the invention is particularly suited to incorporation into topical treatments for wound healing.

20 In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredients including diluents, buffers, binders, disintegrants, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.

Also provided by the invention is a method for treatment of a disease
25 which is treatable by an antimicrobial compound identified using the screening method of the invention. Preferably the antimicrobial compound is a peptide or a peptidomimetic. A therapeutically effective amount of the compound is administered to a subject suffering from, or who is or may have been exposed to, a treatable disease. Treatable diseases preferably include those caused by a
30 pathogenic Gram negative bacterium, and include, for example, enteritis, septicaemia, meningitis, enteric fever, pneumonia, epiglottitis, cellulitis, diarrhea

and sexually transmitted diseases as described above. Plant diseases caused by Gram negative bacteria can also be treated.

EXAMPLES

5

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

10

Example I.

Biotinylation Facilitates the Uptake of Large Peptides by *E. coli* and Other Gram Negative Bacteria

15

Gram negative bacteria such as *Escherichia coli* can normally only take up small peptides less than 650 Daltons, or five to six amino acids, in size. This study provides evidence that large biotinylated peptides can be readily transported into Gram negative bacteria such as *E. coli*. We have found that biotinylated peptides up to 31 amino acids in length can be taken up by *E. coli* and that uptake is dependent on the biotin transporter. Uptake could be competitively inhibited by free biotin or avidin, blocked by the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP), and was abolished in *E. coli* mutants that lacked the biotin transporter. Biotinylated peptides could be used to supplement the growth of a biotin auxotroph and the transported peptides were shown to be localized to the cytoplasm in cell fractionation experiments. The uptake of biotinylated peptides was also demonstrated for two other Gram negative bacteria, *Salmonella typhimurium* and *Pseudomonas aeruginosa*. This finding may make it possible to create new peptide antibiotics that can be used against Gram negative pathogens. Researchers have used various moieties to cause the illicit transport of compounds in bacteria and this study demonstrates the illicit transport of the largest known compound to date.

20

25

30

Materials and Methods

Bacterial strains. *E. coli* MG1655 (wild-type F- λ -), *E. coli* S1036 (Δ bio61 bioP98 (up promoter) *recA1 thi rpsL* λ b515 b519 *galq6 red270 cI857*), *E. coli* S1039 (*birBts13* Δ bio61 bioP98 (up promoter) *recA1 thi rpsL* λ b515 b519 *galq6 red270 cI857*), *E. coli* SA291 (*rpsL his* Δ (*gal-chlA*)), *Pseudomonas aeruginosa* ATCC9721, *S. typhimurium* LT2, and *S. aureus* ATCC25923 were the bacterial strains used in this study. *E. coli* S1036 and S1039 were derived from SK121 which is a derivative of SK98 (Ketner et al., 1975, Proc. Natl. Acad. Sci. USA 7:2698-2702) and contains a mutation in the λ prophage that enables SK121 to grow at 43°C.

Media. Rich LB and minimal M9 media as described by Miller (Miller, 1972, Experiments in Molecular Genetics. Cold Springs Harbor Laboratory Press, Cold Springs Harbor, N. Y.) was used for *E. coli* MG1655 and *S. typhimurium* cultures. Rich LB and minimal media as described by Gilleland et al. (Gilleland, Jr., et al., 1974, J. Bacteriol. 117:302-311) was used for *P. aeruginosa*. Tryptic soy broth and minimal media as described by Mah et al. (Mah et al., 1967, Appl. Microbiol. 15:866-870) was used for *S. aureus*. Rich LB and minimal media as described by Campbell (Campbell, 1961, Virology 14:22-32) was used for *E. coli* S1036, S1039 and SA291. Glucose was the carbon source used in the minimal media for the uptake experiments except for the fractionation studies where maltose was used instead.

Peptides and reagents. The randomized biotinylated peptides XXXX[KBtn]XXXXA (10 amino acids) (SEQ ID NO. 1) and XXXXXXXXXXXXXXX[KBtn]XXXXXXXXXXXXA (31 amino acids) (SEQ ID NO. 2) were synthesized by Sigma Genosys, where A denotes the L-amino acid alanine, X denotes an equimolar mixture of all 20 natural L-amino acids, and KBtn denotes the L-amino acid lysine to which biotin has been attached. The average molecular weight of the 10 and 31 amino acid peptides were determined to be 1,534 and 3,904 Daltons, respectively, using an Applied Biosystems Voyager System 1105 mass spectrometer. This was in very close agreement with the theoretical molecular weights for the 10 and 31 amino acid peptides which were 1,517 and 3,947 Daltons, respectively. Biotin, thiamine,

avidin, and bovine serum albumin were purchased from Sigma. NeutrAvidin Horseradish Peroxidase Conjugate and SuperSignal West Dura Extended Duration Chemiluminescent Substrate were purchased from Pierce.

Uptake assays. Minimal 37°C overnights were diluted into fresh minimal media and incubated at 37°C until they reached an OD₅₅₀ of 0.5. The 10 and 31 amino acid randomized biotinylated peptides were added to the media at a concentration of 1 µg per mL of culture. After addition of the peptide to the culture, 1 mL aliquots were extracted at time intervals up to an hour, washed twice of extracellular peptide using fresh minimal media, then boiled with SDS-PAGE gradient sample buffer. Samples were run on a 10-16% tricine gradient gel (Schägger et al., 1987, Anal. Biochem. 166:368-379) and transferred to nitrocellulose membranes. The resulting Western blots were treated with NeutrAvidin Horseradish Peroxidase Conjugate and SuperSignal West Dura Extended Duration Chemiluminescent Substrate. The membranes were incubated for 5-10 minutes then exposed to X-ray film for 1-10 minutes. Bands on the film were quantified using the AlphaEase 5.5 Densitometry ProGram from Alpha Innotech.

To test the effects that biotin, thiamine, avidin, BSA, or CCCP had on peptide uptake, these compounds were added to mid-log cultures five minutes before the addition of the biotinylated peptide. One mL samples were extracted 10 minutes after the addition of the peptide and analyzed by SDS PAGE as previously described.

An upper 22,500 Dalton protein band can be seen in the western blots involving *E. coli* samples that are shown in Fig. 2, 3, 4, 5, 6 and 8. This band is from the *E. coli* biotin carboxyl carrier protein which is the prominent biotinylated protein in *E. coli* (Fall et al., 1975, Biochim. Biophys. Acta 379:496-503). Multiple upper bands can be seen in the western blots involving *S. typhimurium* and *P. aeruginosa* samples that are shown in Fig. 9. Most bacteria contain several biotinylated proteins and the multiple biotinylated bands seen in the western blots involving *S. typhimurium* and *P. aeruginosa* are consistent with this fact. Additional protein bands ranging from 22,500 to 4,000 Daltons can be seen in the blots involving *E. coli* samples that are shown in Fig. 4 and 8. These

two blots were exposed to film longer than the other blots that are shown in Fig. 2, 3, 5, 6 and 8, and these extra bands are likely extraneous background bands which appear due to overdevelopment of the blot. The biotinylated peptides in Fig. 2 and 9 disappear over time. This is due to degradation by peptidases and proteases that are present in bacterial cells (Walker et al., 2003, J. Peptide Res. 62:214-226) All studies were repeated in triplicate, however, only one representative western blot is shown for each experiment.

Cell fractionation. The 31 amino acid biotinylated peptide was added to *E. coli* MG1655 cells that had been grown to an OD₅₅₀ of 0.5 in minimal maltose media to allow for the induction of the maltose binding protein which served as one of the fractionation controls. After an additional 10 minutes of incubation, the cultures were then subjected to periplasmic shock as described by Ames *et al.* (Ames et al., 1984, J. Bacteriol. 160:1181-1183) to isolate the periplasmic fraction. The remaining cell pellet was then further fractionated using the method described by Altman et al. (1983, J. Bacteriol. 155:1130-1137) to prepare cytoplasmic and membrane fractions with one modification. Cytoplasmic proteins were precipitated by adding trichloroacetic acid at a final concentration of 5% w/v to the cytoplasmic fraction. The precipitate was then centrifuged at 4°C, 50,000 rpm for 30 minutes to pellet the cytoplasmic proteins. The periplasmic, cytoplasmic, and membrane samples were analyzed using a 10-16% tricine gradient gel and Western blotted as described above for the uptake assays.

Results

Biotinylated peptides up to 31 amino acids in length can be taken up by *E. coli*. We initially tested the ability of *E. coli* and *S. aureus* to import a 10 amino acid biotinylated peptide. Randomized peptides were used as opposed to peptides with a specific sequence in order to avoid nonspecific uptake that might be caused by certain amino acid sequences. Peptide was added to mid-log cultures of bacteria which were allowed to incubate for time intervals up to 60 minutes in duration. Samples were removed at specific times, pelleted, washed to remove any peptide in the media that had not been taken up by the cells, and then analyzed as described above.

As shown in Fig. 2, both *E. coli* and *S. aureus* readily imported the 10 amino acid biotinylated peptide. Using densitometry, we determined that up to 75% of the peptide was imported within the first 5 minutes of incubation. To determine whether the import, which was arguably due to biotinylation in *E. coli*,
5 was limited to smaller peptides, we also tested whether a much larger 31 amino acid biotinylated peptide could be imported in *E. coli* and *S. aureus*. As with the 10 amino acid biotinylated peptide, the 31 amino acid biotinylated peptide was also taken up by both *E. coli* and *S. aureus* (data not shown).

The uptake of biotinylated peptides in *E. coli* can be competitively
10 inhibited by biotin or avidin and blocked by the protonophore CCCP. Given that peptides larger than six amino acids cannot be taken up by *E. coli*, the obvious interpretation of our results was that biotin was the mechanism by which this unexpected uptake was occurring. To test this assumption, we conducted a competition experiment in both *E. coli* and *S. aureus* using biotin. We
15 rationalized that since large peptides can be readily taken up by Gram positive bacteria such as *S. aureus*, biotin should have no competitive effect. However, in *E. coli*, if the uptake was due to biotin, then free biotin should be able to competitively block uptake. Fig. 3 shows that this is indeed the case. The uptake of biotinylated peptides could be blocked in *E. coli* by the addition of biotin
20 whereas biotin had no effect on the uptake of biotinylated peptides in *S. aureus*.

Additionally, we showed that the competitive inhibition in *E. coli* was specific to biotin and the use of another similarly sized vitamin, thiamine, had no effect. Because avidin is known to tightly bind biotin (Gilleland, Jr., et al., 1974, J. Bacteriol. 117:302-311), we also tested whether avidin would be able to
25 competitively inhibit the uptake of biotinylated peptides in *E. coli*. Fig. 4 shows that avidin could competitively inhibit the uptake of biotinylated peptides in *E. coli*, but that the use of another similarly sized protein, bovine serum albumin, which is routinely used in *in vitro* studies, had no effect.

It has been shown that biotin uptake is blocked by the protonophore CCCP which disrupts membrane potential in *E. coli* (Piffeteau et al., 1982, Biochim. Biophys. Acta 688:29-36; Piffeteau et al., 1985, Biochim. Biophys. Acta 816:77-82). If the uptake of biotinylated peptides was due to the biotin
5 transport system, then CCCP would be expected to block the uptake of biotinylated peptides. Fig. 5 shows that uptake is blocked when CCCP is added prior to the addition of the biotinylated peptide.

The uptake of biotinylated peptides in *E. coli* is dependent on the biotin transport system. The biotin transport system in *E. coli* has been well
10 characterized and mutants that prevent the uptake of biotin, *birB/bioP*, are available (Campbell et al., 1980, J. Bacteriol. 142:1025-1028; Eisenberg et al., 1975, Bacteriol. 122:66-72). If the import of biotinylated peptides in *E. coli* were indeed due to the biotin transport system, then *birB* mutants should not be able to take up biotinylated peptides. Fig. 6 shows that this is the case. A wild-type
15 *birB*⁺ strain was able to take up biotinylated peptide, while an isogenic *birB*⁻ mutant strain was not.

Biotinylated peptides can be used to fulfill the growth requirements of an *E. coli* biotin auxotroph. To further demonstrate that biotinylated peptides were truly taken up by *E. coli*, we tested whether a biotinylated peptide could be used
20 instead of biotin to fulfill the growth requirement of an *E. coli* biotin auxotroph in minimal media. Fig. 7 shows that an *E. coli* biotin auxotroph grows as well in media supplemented with biotinylated peptide as it does in media supplemented with biotin.

Cell fractionation studies show that the biotinylated peptide can be
25 detected in the cytoplasm of *E. coli*. To demonstrate biochemically that biotinylated peptides were taken up by *E. coli*, we performed cell fractionation studies where periplasmic, cytosolic, and membrane fractions were prepared from cultures to which biotinylated peptide had been added. Fig. 8 shows that the biotinylated peptide localized to both the cytoplasmic and membrane fractions.
30 Of the peptide that could be detected, 66% was found in the membrane fraction and 34% was found in the cytoplasmic fraction. To verify that the cell fractionation studies had been done correctly, we used the same cell fractions to

visualize the GroEL and MBP proteins which are known to localize to the cytoplasm and periplasm, respectively. GroEL was found primarily in the cytoplasmic fraction, while MBP was found primarily in the periplasmic fraction. GroEL's distribution was 93% in the cytoplasm and 7% in the membrane, while
5 MBP's distribution was 95% in the periplasm, 3% in the membrane and 2% in the cytoplasm (data not shown).

Biotinylated peptides can be taken up by other Gram negative bacteria. Given our findings in *E. coli*, we also wanted to test whether biotinylated peptides could be transported by other Gram negative bacteria. We found that
10 both the 10 and 31 amino acid biotinylated peptides could be readily transported by both *S. typhimurium* and *P. aeruginosa*. Fig. 9 shows the uptake of the 31 amino acid biotinylated peptide by *S. typhimurium* and *P. aeruginosa*.

Discussion

15 While conducting an *in vivo* screen for randomly encoded peptides which could inhibit the growth of *Staphylococcus aureus*, we performed a test to confirm that potential peptides resulting from the screen would be readily taken up, as expected, by this Gram positive organism. The synthetic peptides had been biotinylated so they could be easily visualized on Western blots using a
20 neutravidin horseradish peroxidase conjugate. A biotinylated 10 amino acid peptide was added extracellularly to growing cultures of *S. aureus* and an *E. coli* control, since it is well established that Gram negative bacteria such as *E. coli* can only take up very small peptides that are six amino acids or less in size. The *E. coli* control therefore should not have been able to take up the 1,534 dalton
25 peptide. Surprisingly, we found that the peptide was taken up by both *S. aureus* and *E. coli* within 5 minutes of incubation. This observation appeared to contradict the known size exclusion limit of *E. coli* and suggested that the biotinylation of peptides may allow for peptide uptake to occur via the biotin transport system.

30 In this study, we have shown that biotinylation can indeed facilitate the uptake of peptides up to 31 amino acids in length by *E. coli* and that transport is dependent on the biotin transporter, birB/bioP. We have found that the uptake of

the biotinylated peptides can be competitively inhibited by free biotin or avidin, and blocked by the protonophore CCCP which disrupts membrane potential. We also demonstrated that biotinylated peptide could be used to supplement the growth of a biotin auxotroph and that the biotinylated peptide was localized to the cytoplasm in cell fractionation studies. What is known about biotin function in *E. coli* is consistent with our finding that biotin can be used to facilitate the uptake of peptides via the biotin transporter in *E. coli*.

Biotin can be synthesized as well as transported by *E. coli* and the genes involved in biotin biosynthesis and transport are repressible by biotin (Guha, 1971, J. Mol. Biol. 56:53-62). Biotin's transport system is regulated independently of the biosynthetic pathway (Pai, 1973, J. Bacteriol. 116:494-496). *E. coli* readily imports the vitamin biotin when it is available and concomitantly represses biotin synthesis. Biotin uptake is specific, energy dependent, and can accumulate against a concentration gradient (Piffeteau et al., 1982, Biochim. Biophys. Acta 688:29-36; Piffeteau et al., 1985, Biochim. Biophys. Acta 816:77-82; Prakash et al., 1974, J. Bacteriol. 120:785-791). Maximum uptake is observed during exponential growth phase and glucose has been shown to increase biotin uptake slightly. The rate of biotin uptake has also been shown to increase proportionally to the amount of extracellular biotin that is available.

The first mutant that affected biotin transport was discovered by Campbell et al. (1972, Proc. Nat. Acad. Sci. USA 69:676-680). They termed the mutant *bir* for biotin retention and showed that the mutant abolished the ability of *E. coli* to take up biotin. Eisenberg et al. (1975, Bacteriol. 122:66-72) isolated an independent mutant that abolished biotin uptake which they termed *bioP*. Campbell et al. (1980, J. Bacteriol. 142:1025-1028) renamed their original *bir* mutant *birB* and showed that *birB* and *bioP* mutants were identical via genetic mapping experiments.

It is surprising that the biotin transport system can be used to facilitate the uptake of large peptides. Biotin has a molecular weight of 244, making it relatively small in comparison to a 10 amino acid biotinylated peptide with an average molecular weight of 1,534 or a 31 amino acid biotinylated peptide with

an average molecular weight of 3,904. Clearly the biotin uptake system must be flexible since it can accommodate larger molecules. Our finding that 34% of the biotinylated peptide localized to the cytoplasm and 66% of the peptide localized to the membrane is consistent with such a model. Some of the biotinylated
5 peptide was able to completely pass through the biotin transporter while a significant fraction remained in the membrane.

There is contradictory evidence with regard to how biotin's structure affects its ability to be taken up by *E. coli*. Prakash and Eisenberg (Prakash et al., 1974, J. Bacteriol. 120:785-791) stated that while the ureido ring of biotin must
10 be intact for uptake, modification of the side chain has little effect. However, Piffeteau et al. (Piffeteau et al., 1982, Biochim. Biophys. Acta 688:29-36) suggested that modifications to the side chain of biotin could drastically affect biotin's ability to be transported and that the carboxyl group on the side chain is essential for biotin uptake. In the biotinylated peptides used in this study, the
15 biotin carboxyl group is joined to the amino group of lysine via an amide bond and thus the carboxyl group of biotin is not available for recognition. This fact supports Prakash and Eisenberg's argument that the side chain of biotin does not affect uptake. Extrapolation from our data further suggests that it is indeed the ureido ring that is important for recognition and uptake.

20 The fact that biotinylation can facilitate the uptake of very large peptides by Gram negative bacteria represents the illicit transport of the largest known compound to date. Illicit transport has been defined as the entry of compounds into cells through the use of transport systems designed for other substrates (Ames et al., 1973, Proc. Natl. Acad. Sci. USA 70:456-458). There are numerous
25 examples of the use of peptide permeases to facilitate the uptake of small antibacterial peptides or antibiotics that have been coupled to di- or tripeptides (Ames et al., 1973, Proc. Natl. Acad. Sci. USA 70:456-458; Atherton et al., 1980, Antimicrob. Agents Chemother. 18:897-905; Fickel et al., 1973, Nat. New Biol. 241:161-163; Morely et al., 1983, Biochem. Soc. Trans. 11:798-800; Staskawicz
30 et al., 1980, J. Bacteriol. 142:474-479). Additionally, researchers have used various siderophores that are involved in iron uptake to facilitate the transport of antibiotics (Luckey et al., 1972, J. Bacteriol. 111:731-738; Wittmann et al., 2002,

Bioorg. Med. Chem. 10:1659-1670). All of these compounds are much smaller than the 10 and 31 amino acid peptides that we have found to be transported via biotinylation.

5 Interestingly, biotinylated molecules are currently being investigated for drug delivery in mammalian cells. Avidin drugs that bind to biotinylated vectors are being used to promote delivery across the blood brain barrier (Bonfils et al., 1992, Bioconjug. Chem. 3:277-284; Pardridge, 2002, Arch. Neurol. 59:35-40; Song et al., 2002, J. Pharmacol. Exp. Ther. 301:605-610) while antitumor toxins or imaging agents coupled to streptavidin are being delivered using biotinylated
10 antibodies (Hussey et al., 2002, J. Am. Chem. Soc. 124:6265-6273; Press et al., 2001, Blood 98:2535-2543). Biotinylation has also been shown to promote the delivery of polyethylene glycol camptothecin conjugates into human ovarian carcinoma cells (Minko et al., 2002, Cancer Chemother. Pharmacol. 50:143-50) and increase the cellular uptake of polyethylene glycol TAT nonapeptide
15 conjugates into human Caco and CHO cells (Ramanathan et al., 2001, J. Control. Release 77:199-212).

Our finding that biotinylated peptides can be taken up by Gram negative bacteria such as *E. coli*, *S. typhimurium* and *P. aeruginosa*, represents an intriguing possibility for the development of antibacterial peptides. Given the
20 abundance of naturally occurring antibacterial peptides and the increased interest in designing new synthetic peptide drugs, researchers have been trying to develop novel peptide antibiotics that can inhibit the function of key intracellular targets identified through genomics. Researchers have been focusing on Gram positive bacteria where the uptake of large peptides is not problematic. The use of
25 biotinylated peptides may make it possible to use this same approach to develop antibacterial peptides that can target Gram negative bacteria.

The complete disclosures of all patents, patent applications including provisional patent applications, and publications, and electronically available
30 material (e.g., GenBank amino acid and nucleotide sequence submissions) cited herein are incorporated by reference. The foregoing detailed description and examples have been provided for clarity of understanding only. No unnecessary

limitations are to be understood therefrom. The invention is not limited to the exact details shown and described; many variations will be apparent to one skilled in the art and are intended to be included within the invention defined by the claims.

5

What is claimed is:

1. A method for introducing a compound into a Gram negative bacterial cell, the method comprising contacting the cell with a biotinylated compound, wherein the
5 compound comprises a peptide or a peptidomimetic.
2. A method for introducing a compound into a Gram negative bacterial cell, the method comprising contacting the cell with a biotinylated compound to effect delivery of the compound into the cytosol of the cell, wherein the compound
10 comprises a peptide or a peptidomimetic.
3. A method for introducing a compound into a Gram negative bacterial cell, the method comprising contacting the cell, in the absence of a membrane-permeabilizing agent, with a biotinylated compound.
15
4. The method of claim 3 wherein the contact is effective to deliver the compound into the cytosol of the cell.
5. A method for identifying a compound having antimicrobial activity
20 comprising:
 contacting a Gram negative bacterial cell with biotinylated compound to cause uptake of the biotinylated compound by the cell;
 determining whether the biotinylated compound has an antimicrobial effect on the cell.
25
6. The method of any one of claims 1, 2 or 5 wherein the cell is contacted with the biotinylated compound in the absence of a membrane-permeabilizing agent.
7. The method of any of claims 3 to 6 wherein the compound comprises a
30 peptide or a peptidomimetic.

8. The method of any of the preceding claims further comprising linking a biotin moiety to the compound to yield the biotinylated compound.
9. The method of any of the preceding claims wherein the biotinylated
5 compound comprises a biotin moiety covalently linked to the compound through a biotin carboxyl group.
10. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising least 2 amino acids.
- 10 11. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising at least 5 amino acids.
12. The method of any of the preceding claims wherein the compound comprises
15 a peptide or peptidomimetic comprising at least 10 amino acids.
13. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising at least 20 amino acids.
- 20 14. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising between 10 and 31 amino acids.
15. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising between 10 and 50 amino acids.
- 25 16. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising between 10 and 60 amino acids.
17. The method of any of the preceding claims wherein the compound comprises
30 a peptide or peptidomimetic comprising between 10 and 70 amino acids.

18. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising between 10 and 80 amino acids
19. The method of any of the preceding claims wherein the compound comprises
5 a peptide or peptidomimetic comprising between 10 and 90 amino acids
20. The method of any of the preceding claims wherein the compound comprises a peptide or peptidomimetic comprising between 10 and 100 amino acids
- 10 21. The method of any of claims 1, 2, or 7 to 20 wherein the peptide or peptidomimetic is conjugated to a bioactive compound.
22. The method of any of the preceding claims wherein the Gram negative bacterial cell is a cell of the genus *Escherichia*, *Salmonella*, or *Pseudomonas*.
15
23. The method of any of the preceding claims wherein the Gram negative bacterial cell is an *E. coli* cell, a *S. typhimurium* cell, or a *P. aeruginosa* cell.
24. The method of any of the preceding claims wherein the Gram negative
20 bacterial cell comprises a biotin transporter.
25. The method of claim 24 where the biotin transporter comprises a *birB/bioP* transporter.
- 25 26. The method of any of the preceding claims wherein the compound comprises a therapeutic, diagnostic or imaging agent.
27. The method of any of the preceding claims wherein the compound further comprises a targeting moiety that specifically targets a Gram negative bacterial
30 cell.

28. The method of claim 27 wherein the targeting moiety comprises a receptor ligand or an antibody or fragment thereof.
29. The method of any of the preceding claims wherein the compound comprises
5 an antibiotic.
30. The method of any of the preceding claims wherein the compound, prior to biotinylation, comprises a naturally occurring peptide.
- 10 31. The method of any of the preceding claims wherein the compound, prior to biotinylation, comprises a synthetic peptide.
32. The method of any of the preceding claims wherein the Gram negative bacterial cell is a pathogen.
15
33. The method of any of the preceding claims wherein the compound, when introduced into the cell, inhibits the growth of the cell.
34. The method of any of the preceding claims wherein the compound, when
20 introduced into the cell, causes the death of the cell.
35. The method of any of the preceding claims performed in the absence of calcium chloride.
- 25 36. A compound identified by the method for identifying a compound having antimicrobial activity as in any of claims 5 through 35.
37. A pharmaceutical composition comprising an effective amount of the compound of claim 36 and a pharmaceutically acceptable carrier.
30

38. A method for the treatment of a disease treatable by the compound of claim 36, the method comprising administering to a patient in need thereof a therapeutically effective amount of said compound.


5 39. The method of claim 38 wherein the disease is caused by a pathogenic Gram negative bacterium.

40. Use of the compound of claim 36 for preparation of a pharmaceutical composition for treatment of a disease caused by a Gram negative bacterium.

10

41. The compound of claim 36 for use as a medicament for treatment of a disease caused by a Gram negative bacterium.

42. The method of any of claims 38 to 41 wherein the disease is selected from
15 the group consisting of enteritis, septicaemia, meningitis, enteric fever, pneumonia, epiglottitis, cellulitis, diarrhea and a sexually transmitted disease.



Biotin

Figure 1





Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 May 2005 (26.05.2005)

PCT

(10) International Publication Number
WO 2005/046730 A3

(51) International Patent Classification:
A61K 47/48 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:
PCT/US2004/037896

(22) International Filing Date:
12 November 2004 (12.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/519,100 12 November 2003 (12.11.2003) US

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.** [US/US]; Boyd Graduate Studies Research Center, Athens, GA 30602-7411 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ALTMAN, Elliot** [US/US]; 210 Great Oak Drive, Athens, GA 30605-4505 (US). **WALKER, Jennifer, R.** [US/US]; 2980 Rocky Branch Road, Bogart, GA 30622 (US).

(74) Agent: **SANDBERG, Victoria, A.**; Muetting, Raasch & Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN 55458-1415 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
21 September 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BIOTIN-FACILITATED TRANSPORT INTO GRAM NEGATIVE BACTERIA

(57) Abstract: The invention provides a method for biotin-facilitated introduction of a compound into a bacterial cell, preferably a Gram negative bacterial cell. The compound to be introduced into the cell is biotinylated, and the biotinylated compound is contacted with the cell to effect delivery of the compound to the cell. Advantageously, the biotinylated compound can pass through both the inner and outer cell membranes and is delivered to the cytosol of the cell. A biotinylated compound can be delivered to any Gram negative bacterial cell capable of transporting biotin from the extracellular environment to the intracellular environment.



WO 2005/046730 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/037896

A. CLASSIFICATION OF SUBJECT MATTER

INV. A61K47/48 A61P31/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EP0-Internal, BIOSIS, EMBASE, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DARGIS M ET AL: "Use of biotinylated beta-lactams and chemiluminescence for study and purification of penicillin-binding proteins in bacteria." ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 38, no. 5, May 1994 (1994-05), pages 973-980, XP002374249 ISSN: 0066-4804 abstract page 975, right-hand column, last paragraph	1-4,6-35
X	WO 99/06440 A (ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAM; APPELMELK, BE) 11 February 1999 (1999-02-11) page 15, line 22 - page 17, line 5 ----- -/--	1-4,6-35

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

28 March 2006

Date of mailing of the international search report

- 3. 07. 2006

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dullaart, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/037896

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DE 100 55 789 A1 (PHARMA-ZENTRALE GMBH) 6 June 2002 (2002-06-06) examples	1-4,6-35
X	----- RAMANATHAN S ET AL: "Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide" JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 77, no. 3, 13 December 2001 (2001-12-13), pages 199-212, XP004328573 ISSN: 0168-3659 cited in the application page 200, right-hand column, last paragraph - page 201, right-hand column -----	1-4,6-35
X	WO 98/52614 A (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; ROTHBA) 26 November 1998 (1998-11-26) examples 8,11 -----	1-4,6-35
X	WO 90/12096 A (PURDUE RESEARCH FOUNDATION) 18 October 1990 (1990-10-18) example 12 -----	1-4,6-35
X	LING LING CHEN ET AL: "INCREASED CELLULAR UPTAKE OF THE HUMAN IMMUNODEFICIENCY VIRUS-1 TATPROTEIN AFTER MODIFICATION WITH BIOTIN" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 227, 1995, pages 168-175, XP002927982 ISSN: 0003-2697 page 168, right-hand column page 169, right-hand column figures 2,3,5 -----	1-4,6-35
Y	EP 1 036 798 A (HISAMITSU PHARMACEUTICAL CO. INC; HISAMITSU PHARMACEUTICAL CO., INC) 20 September 2000 (2000-09-20) example 1 -----	1-4,6-35
Y	WO 95/31556 A (UNILEVER NV; UNILEVER PLC) 23 November 1995 (1995-11-23) example 1 -----	1-4,6-35
Y	STOLZ ET AL: "rapid purification of a functionally active sucrose carrier from transgenic yeast using a bacterial biotin acceptor domain" FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, no. 377, 1995, pages 167-171, XP002079374 ISSN: 0014-5793 page 167 - page 168 -----	1-4,6-35
	----- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2004/037896

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 976 535 A (FRITZBERG ET AL) 2 November 1999 (1999-11-02) the whole document -----	1-4,6-35
Y	OTVOS LASZLO JR ET AL: "Interaction between heat shock proteins and antimicrobial peptides" BIOCHEMISTRY, vol. 39, no. 46, 21 November 2000 (2000-11-21), pages 14150-14159, XP002374250 ISSN: 0006-2960 abstract page 14151, right-hand column - page 14152, left-hand column -----	1-4,6-35
E	WO 2005/032598 A (THE GENERAL HOSPITAL CORPORATION; ELMALEH, DAVID, R; SHOUP, TIMOTHY, M) 14 April 2005 (2005-04-14) page 2, last paragraph - page 3, line 10 page 42, line 30 - page 43, line 7 page 44, line 23 - line 32 -----	1-4,6-35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2004/037896

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

6-35 (partially), 1-4

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-4, and part of 6-35

A method of introducing a compound into a Gram negative bacterial cell as claimed.

2. claims: 5, and part of 6-35

Method for identifying a compound having antimicrobial activity according to these claims.

3. claims: 36-42

An antimicrobial compound, a pharmaceutical composition containing it, a method of treatment in which it is used, and its first or second medical use as defined in these claims.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/037896

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9906440	A	11-02-1999	AU 759636 B2	17-04-2003
			AU 3787097 A	22-02-1999
			CA 2298101 A1	11-02-1999
			EP 0988314 A1	29-03-2000
			JP 2001512140 T	21-08-2001
			US 6624140 B1	23-09-2003
DE 10055789	A1	06-06-2002	AU 3722002 A	27-05-2002
			WO 0240511 A2	23-05-2002
WO 9852614	A	26-11-1998	AT 251913 T	15-11-2003
			AU 734827 B2	21-06-2001
			AU 7593898 A	11-12-1998
			BR 9809138 A	28-08-2001
			CA 2291074 A1	26-11-1998
			CN 1263473 A	16-08-2000
			DE 69818987 D1	20-11-2003
			DE 69818987 T2	29-07-2004
			EP 0975370 A2	02-02-2000
			ES 2210761 T3	01-07-2004
			GB 2341390 A	15-03-2000
			JP 2002502376 T	22-01-2002
			PL 337033 A1	31-07-2000
WO 9012096	A	18-10-1990	AT 160583 T	15-12-1997
			AU 5437590 A	05-11-1990
			CA 2013580 A1	03-10-1990
			CA 2013582 A1	03-10-1990
			DE 69031763 D1	08-01-1998
			DE 69031763 T2	25-06-1998
			DK 466816 T3	10-08-1998
			EP 0466816 A1	22-01-1992
			ES 2113346 T3	01-05-1998
			IE 901201 A1	09-10-1991
			IL 93983 A	18-02-1997
			JP 5502787 T	20-05-1993
			JP 3232347 B2	26-11-2001
			PT 93646 A	20-11-1990
			US 5108921 A	28-04-1992
			US 5416016 A	16-05-1995
EP 1036798	A	20-09-2000	AT 245168 T	15-08-2003
			DE 60003860 D1	21-08-2003
			DE 60003860 T2	05-02-2004
			JP 2000264900 A	26-09-2000
			US 6451971 B1	17-09-2002
WO 9531556	A	23-11-1995	EP 0759081 A1	26-02-1997
			JP 10500127 T	06-01-1998
US 5976535	A	02-11-1999	NONE	
WO 2005032598	A	14-04-2005	AU 2004277403 A1	14-04-2005
			CA 2540131 A1	14-04-2005